AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

AbbVie presents 22 IBD abstracts and AbbVie stock costs EUR 247.55

Acquisition Drug approval Earnings report AI-generated analysis

πŸ“ˆ AbbVie reported second-quarter 2026 revenue of USD 16.99 billion, a 10.20 percent year-over-year increase.

πŸ’° Adjusted earnings per share reached USD 3.65, surpassing the USD 3.61 consensus estimate.

πŸ”¬ RINVOQ data showed 93.30 percent clinical and steroid-free remission in fistulizing disease patients.

🧬 SKYRIZI Phase 3 AFFIRM results and long-term extension data were presented at the ACG meeting.

πŸ“‰ AbbVie completed its Apogee Therapeutics acquisition for USD 10.9 billion on September 3, 2026.

πŸ’Ό Guggenheim reaffirmed a Buy rating with a USD 288.00 price target for the company.

πŸ“… Third-quarter 2026 earnings are scheduled to be announced on October 30, 2026.

πŸ₯ The company presented 22 inflammatory bowel disease abstracts at the ACG meeting in October 2026.

πŸ’Ή Stock price rose to EUR 247.55, up 0.75 percent versus the previous close.

πŸ“Š 58.00 percent of patients with isolated ileal disease achieved endoscopic response on RINVOQ.

Bullish Signals
  • AbbVie reported second-quarter 2026 revenue of USD 16.99 billion, up 10.20 percent year over year.
  • Adjusted earnings per share reached USD 3.65, beating the USD 3.61 consensus estimate.
  • RINVOQ achieved 93.30 percent clinical and steroid-free remission in fistulizing disease patients.
  • SKYRIZI Phase 3 AFFIRM results and long-term extension data were successfully presented at the ACG meeting.
  • Guggenheim reaffirmed a Buy rating with a USD 288.00 price target, indicating analyst confidence.
  • The company demonstrated strong real-world evidence with 57.00 percent clinical remission in isolated ileal disease.
Full Analysis
AbbVie Inc. announced the presentation of 22 abstracts focused on inflammatory bowel disease at the American College of Gastroenterology (ACG) meeting held in October 2026. The company highlighted significant clinical data for its key products, SKYRIZI and RINVOQ, demonstrating strong efficacy in treating fistulizing disease and isolated ileal disease with high rates of steroid-free remission. Financially, AbbVie reported robust second-quarter 2026 results with revenue reaching USD 16.99 billion, representing a 10.20 percent year-over-year increase. Adjusted earnings per share stood at USD 3.65, which beat the consensus estimate of USD 3.61. Following these results and the positive clinical data presentation, the stock price appreciated to EUR 247.55. The company recently completed its acquisition of Apogee Therapeutics for USD 10.9 billion, with initial R&D expenses totaling USD 216 million recorded in October. Analysts remain bullish on the stock, with Guggenheim reaffirming a Buy rating and setting a price target of USD 288.00, reflecting confidence in AbbVie's pipeline and execution capabilities. Looking ahead, investors will await AbbVie's third-quarter 2026 earnings report scheduled for October 30, 2026. The company continues to leverage its immunology portfolio, presenting both controlled trial evidence and real-world treatment outcomes to reinforce its market position in gastroenterology.